Search results

Innunity is a preclinical biotech focused on developing a portfolio of novel small molecule CLR pathway inhibitors for innate-immune-driven disorders.  

Cell Receptor Inc. has IP for remarkably improving treatment results in oncology by targeting critical upstream steps of growth signaling, not noticed in oncology yet. A well-tolerated treatment of low toxicity! It will prevent metastasis and chemoresistance in most cancers.

HyQure BioTech is a Basel–Shanghai biosafety CRO supporting biologics, vaccines and cell & gene therapy. We provide viral clearance, cell bank characterization, replication-competent virus assays, lot-release/QC testing, and regulatory-ready data for global filings.

Rhynexa develops clonal, potency-defined off-the-shelf mesenchymal stromal cell (MSC) therapies. Its platform is designed to generate one defined MSC clone per indication, enabling more consistent and scalable treatment, initially focused on SR-aGVHD.

ZH-based company that focuses on innovative solutions in the biotechnology sector. The company concentrates on the scientific development of novel therapeutic approaches that aim to address previously underserved medical challenges and difficult-to-treat diseases.

Blue Wave Therapeutics is a Swiss biotech developing radioligand therapies for hard-to-treat cancers. It leverages a flexible biopolymer-based platform supporting nanoparticle, gel and IV formulations for targeted radiation delivery. The lead program focuses on recurrent glioblastoma.

Crearene is a pioneering, patient centric medical technology company, with the mission to bring the human dimension into dialysis treatments. Following a successful safety, feasibility, and dose-finding clinical study, Crearene now intends to launch its fist commercial offering into the market.

VERAXA is a Swiss/German clinical-stage company advancing next-generation antibody therapies to fight cancer through groundbreaking innovations. Using a dual-targeting approach, our BiTAC-TCE, BiTAC-ADC, and bsADC platforms are powered by proprietary chemical bioconjugation and linker technologies.

Inventprise is a biotechnology company dedicated to inventing and developing affordable, high-impact vaccines that address critical unmet needs worldwide. Pipeline candidates include Group B Streptococcus, Shigella, Klebsiella and mRNA, as well as next-generation DMAP delivery technology.

Galvita develops a patented and clinically validated oral drug delivery platform. The microcapsules can be loaded with active ingredients from all BCS-classes as well as peptides, and can easily be compressed into ODTs with excellent mechanical strength and very fast disintegration.

Stealth Radiopharma is a biotechnology company advancing the next generation of precision radiopharmaceuticals for patients with cancer.

Combioxin is a clinical-stage biotechnology company dedicated to the development of first-in-class life-saving drugs for critically ill patients.

Melodia Therapeutics is advancing a next-generation DPP1 inhibitor to transform the treatment of severe neutrophil-driven inflammatory diseases.

HemostOD is a seed financed start-up developing in-vitro human platelets. It has 10 staff, 8 of which are based at laboratories on the EPFL Innovation park in Lausanne. With operations commencing in 2021, HemostOD's next milestone is a pre-IND meeting in 2026 and commencement of IND studies.

Arakena Pharmaceuticals AG is a Basel-based biopharma start-up, focusing on the discovery and development of innovative small molecular weight compounds as first-in-class treatment for cardiomyopathies, cardiovascular and metabolic diseases.

THE CULTURED HUB works with a global network of start-ups to find answers to the food industry’s most pressing questions in order to define the food of the future. We are a scale up as a service company for industrial biotech, accelerating the development of sustainable foods through biotech.

Discover if your new anti-cancer drug will work! Our validated platform uses intact patients tumors, maintains their complexity and cellular component, and overcomes organoids. This allows to reliably assess at the pre-clinical stage the efficacy of drugs in patients.

We are using ethical and representative AI technology to pioneer groundbreaking health ventures that transform health journeys, empowering communities in the global south. Our cutting-edge technology can address complex healthcare challenges and make a meaningful impact on people's lives.

LifeMine is a biopharmaceutical company that leverages evolutionary insights from fungi to unearth next-generation precision medicines. Through our discovery engine, we are uniquely positioned to bring novel precision medicines to patients in urgent need of breakthrough disease intervention.

Cureteq is an asset management and biotechnology company developing innovative medicines based on a sophisticated artificial intelligence platform. Cureteq leverages artificial intelligence to identify the optimal applications of a given molecule and to de-risk clinical development.

Abrinca delivers an end-to-end software platform for analysis and management of microbial genomes, transforming raw DNA data into high-value digital assets to fuel the next wave of bio-innovation.

Ironwood Pharmaceuticals is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients.

Renaldee is bringing the first natural active form of Vit. D (1,25-dihydroxyvitamin D3) into a human pharma market extracted entirely from a plant, solanum glaucophyllum. Our offering is not to be confused with the inactive form of Vit. D which you can buy over the counter.

AdRegeneer exists to redefine neuroregeneration and restore hope for patients suffering from neurodegenerative diseases. We believe that regeneration is possible, and we are committed to developing innovative, patient-centric therapies that go beyond symptom management.

Adjuvants are key ingredients of vaccines, improving the duration of immune responses or making vaccines cheaper to produce. VFI’s mission is to develop high-quality adjuvants for the benefit of the vaccine community and make them accessible under equitable and open-access terms.

Metadvice Companion AI is distilling complex disease treatment outcome data into actionable insights shared with clinicians & patients, sourcing data from a growing global network of leading practitioners to take precision medicine to the next level!

We produce medical cannabis as a recognized remedy for the benefit of patients. Canexis is committed to bringing the highest quality cannabinoids to the market for medical purposes. To ensure this, we work consistently in accordance with the EU or PIC/S-GMP (part 1 & part 2) regulations.

We are a dynamic and forward thinking pharmaceutical and biotechnology company from Zug. We develop a portfolio ot treatmens to common conditions in Gynaecology, CNS, Cardio that are difficult to treat and often have limited alternatives.

Inhalis is committed to improve patients’ life with safer and more effective treatment options. Solid science and industry-leading delivery technology are combined with an experienced management team to research and develop new inhaled treatments for IPF and other life-threatening diseases.

Swiss Bioscience was established in 2014 in Switzerland and is specialized in producing pharmaceutical quality grade stems cells under cGMP* conditions. The cells are isolated from human adipose tissue to produce SVF which is then purified and expanded to produce hADSCs.

3B Biotech is a Swiss-based full service Contract Research Organization, Regulatory affairs and Pharmacovigilance specialist. Our solutions support pharma, biotech, medical and nutritional companies during the development, research, marketing and post-marketing programs. 

LaRive Bio is a clinical development and licensing organization founded in 2021 and based in Zug. We seek to identify, license in/acquire, develop and license out molecules in areas of significant unmet medical need, applying an abbreviated regulatory pathway. At present, focus lies on neurology.

Van Hoef Consulting by Marlies Van Hoef, MD, PhD, MBA, provides medical and scientific services to biopharma and biotech companies in clinical development and medical affairs, including regulatory and safety aspects. Specialized in oncology, hematology and hematopoietic cell transplantation.

Swixx represents the portfolio of biopharma multinationals in markets they choose not to enter or exit.  We are present in 50+ countries in Central and Eastern Europe, MENA, Eurasia/CIS and LATAM. With >2,000 employees, Swixx is one of the largest commercialization platforms for biopharma companies.

IBEX Therapeutics SA developd an innovative mouthwash and a portfolio of products based on medicinal plant extracts, to prevent and treat chemoradiotherapy-induced oral mucositis in patients with cancer.

CanSinoBIO (SSE: 688185, HKEX: 06185) commits to research, production and commercialization of innovative vaccines. It possesses five integrated platform technologies including adenovirus-based vectors, conjugation, protein design and recombination, formulation and mRNA www.cansinotech.com

plusbiome is providing consultancy services in the area of health and life science.

Micreos is a platform biotech company focused on discovering and developing recombinant proteins for chronic dermatology, oncology, and respiratory conditions.

We are a National Center of Excellence for Translational Medicine that accelerates and streamlines research for the benefit of patients, society and science. Located on the INSEL CAMPUS BERN, a wide variety of units from the hospital, industry, research, and education are networked under our roof.

BioFi’s proprietary technology Endogenics™ is a novel approach to virtual modeling and simulation for living organisms. From simple single cells to complex and dynamic multicellular systems. We work across Life Sciences industries to investigate biological mechanisms, generating knowledge and IP.

GRIFFON develops peptides against metabolic disorders.

Endogena is a clinical-stage biotechnology company that discovers and develops first-in-class endogenous regenerative medicines to repair diseased tissues. Our unique approach has the potential for a paradigm shift in how degenerative conditions due to aging and genetic disorders are treated.

For small and medium‑sized biotech and pharmaceutical companies and their service providers, Marvapharm offers commercial consultancy services and access to an international network, to support business development, product acquisition, and the provision of pharmaceutical products and services, including ga

Biotechnet Switzerland is an association of Swiss Universities of Applied Sciences, Universities, and Research and Technology Organizations. Industrial partners can rely on our proven expertise and outstanding infrastructure to support innovative research & development projects.

Expertise in exploratory clinical drug/diagnostic development is available across a number of disease areas. Timing of input into the developmental strategy from regulatory and commercial perspectives is important in moving development programs towards success.

Our fingerprint: knowhow, network, and capital. ADYA is a Swiss Investment boutique in the life sciences sector that provides strategic consulting, C-level management and access to capital to SMEs and offers a unique service to investors clients looking for investments and asset allocation.

Quercis Pharma AG is a private Swiss biotech company advancing a novel antithrombotic in multiple indications: the lead program is prevention of Venous Thrombosis Embolism in advanced cancer patients (phase III) followed by clinical trials in Sickle Cell Disease (phase II) and Covid-19 (phase II).

Ridgeline, a Versant Ventures Discovery Engine, was founded in early 2017 to create and operate Versant-financed innovative biotech companies in Basel, Switzerland.

Holding, management consulting & strategy advisory focused on biotech, medtech, nutraceuticals and health services. Our strong knowledge of international competitive and synergistic landscape and our large network of strategic partners help our clients to expand into new jurisdictions and markets.

MphaR is a company providing a full range of services in the area of Medical Affairs in Oncology, Neurology and Rare Disease TA. We assist clients who develop innovative therapies. As a digital solution for the pharmaceutical industry, MphaR offers Virtual Advisory Board Platform.

NxR Biotechnologies®, assists companies or academia in business development or investment initiatives, strategic, scientific, and commercial projects, with a focus on ATMPs. In parallel, NxR conducts internal R&D in oncology. Track record comprises projects with big pharmas, generic companies, financial

Maintenance-free cell culture analyzer technology, BioProfile FLEX2. With autosampling from ambr® 15 and 250 cell culture systems, FLEX2 provides key chemistries and gases, cell density, viability, and osmolality with single sample and data output stream.

Cureab is a biotech company focused on discovering and developing antibodies in oncology until late pre-clinical stage.

Recordati is an international pharmaceutical group, listed on the Italian Stock Exchange dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, North and South America and Asia.

Valerius Biopharma AG develop biosimilar drugs for therapeutic indications with high medical need. The product pipeline consists of four orphan and non-orphan biosimilar drugs that will be developed according to highest regulatory standards to enable global access for patients at affordable prices.

GARDP’s mission is to work in partnership with the public and private sectors to develop and deliver new treatments for bacterial infections where drug resistance is present or emerging, or for which inadequate treatment exists.

Rare Diseases - Your gateway to the Swiss market Seventeen Pharma Sàrl is providing services to biotech companies willing to commercialize Orphan Drugs in the Swiss market. From PRE-APPROVAL to POST-APPROVAL support. [email protected]

PharmaFox (PhFx) develops biologicals for the treatment of muscle disorders. PhFx has obtained strong preclinical proof of concept with its proprietary compound increasing muscle strength and endurance in mice. PhFx is preparing for Phase I studies and looking for its first round of investment

Phi Pharma SA is developing a new class of anti-cancer drugs: Peptide Drug Conjugates (PDCs) effective in multiple human cancers using an innovative mechanism of cell entry: novel CSPG4 targeting bio-pharmaceuticals.

Primex Pharmaceuticals is a leading global innovative anaesthesia company, expanding in paediatric pharmaceuticals.

Consulting company in health care, medical devices and cosmeceuticals.

PB&B SA is a Swiss deep-tech company advancing a patented PLGA-microsphere platform for natural adipose regeneration. Our lead product, PBB-002, targets long-lasting aesthetic restoration.

Dottikon ES is a Swiss CDMO for small molecules, supporting biotech and pharma partners from early development to commercial supply. With deep expertise in hazardous chemistry, Dottikon enables efficient, scalable, and reliable manufacturing solutions.

Auctris Life Sciences, manages critical development and operational situations within pharma/biotech by finding solutions to challenges on projects portfolio, product development, manufacturing, supply chain and quality to secure business continuity and achieve your company objectives.

Axalbion is a clinical-stage pharmaceutical company developing TRPM8 agonists for the treatment of chronic cough. Axalbion’s s strategy is to develop its lead compound AX-8 up-to Phase 2b to show clinical proof of concept across a representative patient population.

MEMS's are semi-allergens recognizing the chemically modified and polymerized sequences of proteins that accumulate in aging and infection. The protein rubbish occludes the membrane's receptors and causes cell degeneration and autoimmunity. MEMS’s lead to the elimination of waste-stopping pathology.

TwentyGreen SA develops scalable bioprocess technologies for the cultivation of beneficial human gut archaea. We are advancing industrial production of Methanobrevibacter smithii to enable next-generation microbiome therapeutics, diagnostics, precision nutrition, and research applications.

Cannapharm AG produces cannabis based raw material for the production of pharmaceuticals and cannabis based extracts for pharmacies.

100% subsidiary of Merck & Co., Inc., USA. Process development and pilot manufacturing of biopharmaceuticals.

Phoenixus AG is a fully integrated biopharmaceutical company focusing on patients with unmet medical needs.

VAXIMM is developing oral T-cell immunotherapies for cancer patients. Its technology is based on first-in-class oral T-cell activators, using modified attenuated bacteria carrying a eukaryotic expression plasmid, which enables the targeting of tumor-related antigens, including personalized neoantigens.

Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 300 employees in Switzerland and abroad. Tillotts is dedicated to the development, in/out-licensing and commercialisation of innovative pharmaceutical products for the digestive system.

We are a market-leading pharma and biotechnology international company based in Switzerland. TRB Chemedica was founded in 1980. TRB remains a family-owned company dedicated to advancing healthcare in ophthalmology and rheumatology. We prioritize patients, physicians and actively involving experts.

Target BioScience AG is a consulting and service company engaged in market access, regulatory affairs and quality systems for pharmaceuticals and biotechnology products. Target BioScience AG has regulatory authorization to register and market pharmaceutical products in Switzerland.

Shield is a commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.

scienceindustries, the Swiss Business Association Chemistry Pharma Life Sciences, supports some 250 member companies: fostering an innovation-friendly environment, creating a competitive production and business framework, enabling attractive market conditions, and facilitating global market access.

Servier is an independant pharmaceutical company commited to therapeutic progress to serve patient needs. Its unique governance allows Servier to reinvest all its profits to support its development, as well as plan and invest with a long-term view, in line with its vocation.

We partner with international pharmaceutical companies to act as Swiss marketing authorization holder and commercialize innovative medicines onto the Swiss market. Our teams are highly experienced and provide in-depth expertise of commercial operations in domains like oncology and rare diseases. SFL Pharma ha

Redbiotec was founded in 2006 as an ETH spin-off. Having sold its CMV vaccine business to Pfizer in 2015, Redbiotec has since developed potent HSV-2 immunotherapies, and a platform technology of engineered bacteria - BRISPR® - to deliver therapeutic cargos of various nature for the treatment of cancer and ge

MindMaze Therapeutics is a global leader in brain technology, dedicated to redefining the recovery trajectory for patients with neurological platform-based digital treatments.

Roivant delivers R&D solutions to the biopharmaceutical industry and academic institutions through partnerships designed to realize the full potential of promising biomedical research.

Kerecis is a life science company that develops or acquires intellectual property from natural product extracts, defines scientifically sound development protocols, manages product development and then seeks exit options for these developed medicines (primarily healing of acute and chronic wounds).

Company highlights Octapharma is a global healthcare company headquartered in Lachen, Switzerland. Family-owned since being established in 1983. The largest independent plasma fractionator in the world. 5 state-of-the-art manufacturing sites. >190 own plasma donation centers across Europe and the US.

NeuroAssets, a leading trans-Atlantic neuroscience consultancy, works with Pharma, Biotech and Foundations on strategic, operational, scientific, clinical, regulatory, business development and financing aspects. Clients include private and public biotech companies in Europe, USA and Japan.

A private pharmaceutical company re-purposing an existing approved drug for a new indication. N-003 (ambrisentan) may be the first therapy for portal hypertension and its complications in patients with liver cirrhosis.

Neurim Pharmaceuticals is a neuroscience drug discovery and development company creating drugs for brain restoration & reinforcement, focusing on the central nervous system.

NDA is a leading regulatory drug & device development consultancy, supporting companies with their regulatory, pharmacovigilance, quality and strategic communication challenges across the US and Europe, from concept to commercialization.

LASCCO SA is a biomedical-technology development private company based at the Biopole of Lausanne, Switzerland.

Private biotech company focused on developing modulators of intracellular protein-protein interactions employing a proprietary technology platform. The most advanced of these first-in-class therapeutics, an oral modulator of dysregulated transcription, is currently in preclinical development.

Programs identify therapies and integrate molecular techniques in clinical trials for solid tumors, especially prostate cancer, and hematological cancers. Strict links to IOSI, SAKK or IELSG cooperative groups. IOR also owns the patent of novel anticancer molecules.

Janssen is one of the world's leading companies in the research and development of innovative medicines. As part of the Johnson & Johnson healthcare group, we focus on some of the greatest medical challenges of our time.

Inflamalps is a biopharmaceutical company established in Valais, Switzerland. Our mission is ‘’to discover and develop novel medicines to treat inflammation with a focus on chronic inflammatory diseases of the eye and of the skin”.

Geistlich Pharma is specialized in biomaterials for the regeneration of bone, cartilage and tissue and develops and manufactures medical devices and pharmaceuticals with the goal of giving patients a better quality of life.

EpiPharm is a clinical-stage company developing new treatment concepts for melanocytic and non-melanocytic pigmented lesions, unmet medical and dermato-cosmetic needs. Current focus is on the application of proprietary plant extracts for dermato-cosmetic applications.

The objective of Dorphan is the preclinical and clinical development of innovative therapeutic solutions for orphan and rare genetic diseases affecting mainly children, with a strong focus on two related lysosomal storage diseases, GM1-gangliosidosis and Morquio disease type B.

COPEXIS S.A. is a quality-driven consultancy firm with expertise in drug development (manufacturing, safety/toxicology, clinical, regulatory), drug regulatory services (CH/EU), corporate development and management.

CARBOGEN AMCIS is a leading provider of drug development and commercialization services to pharmaceutical and biopharmaceutical companies across all development stages.

The group, offering state-of-the-art regenerative medicine solutions, has developed a technology platform that gave birth to therapies aiming at tissue regeneration across different applications, in order to provide pertinent and sustainable solutions leveraging the human's natural endowment.

AlloCyte Pharmaceuticals AG is a Swiss-based company discovering, developing and commercializing next generation oral integrin modulators of allosteric mode of action protecting the integrity of tissues afflicted by autoimmunity. The next target milestone is clinical therapeutic proof-of-concept.